14-day Premium Trial Subscription Try For FreeTry Free
$229.84
+13.79 (+6.38%)
At Close: May 03, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $141.16 $183.01 Friday, 3rd May 2024 MDGL stock ended at $229.84. This is 6.38% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 5.88% from a day low at $221.25 to a day high of $234.25.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Madrigal Pharmaceuticals, Inc. prices

Date Open High Low Close Volume
Jun 29, 2016 $0.290 $0.290 $0.261 $0.268 677 054
Jun 28, 2016 $0.262 $0.295 $0.255 $0.280 624 503
Jun 27, 2016 $0.310 $0.345 $0.260 $0.261 1 070 441
Jun 24, 2016 $0.310 $0.320 $0.302 $0.308 8 506 472
Jun 23, 2016 $0.310 $0.340 $0.310 $0.315 719 932
Jun 22, 2016 $0.310 $0.320 $0.305 $0.310 424 898
Jun 21, 2016 $0.318 $0.320 $0.310 $0.311 421 745
Jun 20, 2016 $0.340 $0.355 $0.320 $0.324 720 798
Jun 17, 2016 $0.330 $0.340 $0.312 $0.340 506 039
Jun 16, 2016 $0.310 $0.340 $0.302 $0.318 429 096
Jun 15, 2016 $0.306 $0.339 $0.300 $0.310 264 027
Jun 14, 2016 $0.340 $0.350 $0.310 $0.310 567 967
Jun 13, 2016 $0.350 $0.365 $0.312 $0.336 1 169 531
Jun 10, 2016 $0.360 $0.365 $0.350 $0.351 544 391
Jun 09, 2016 $0.370 $0.376 $0.360 $0.360 205 952
Jun 08, 2016 $0.370 $0.375 $0.356 $0.366 368 358
Jun 07, 2016 $0.362 $0.380 $0.357 $0.360 446 877
Jun 06, 2016 $0.356 $0.380 $0.356 $0.377 249 432
Jun 03, 2016 $0.370 $0.370 $0.357 $0.370 239 892
Jun 02, 2016 $0.363 $0.370 $0.356 $0.360 434 073
Jun 01, 2016 $0.351 $0.375 $0.351 $0.370 260 047
May 31, 2016 $0.370 $0.375 $0.350 $0.350 1 174 633
May 27, 2016 $0.379 $0.385 $0.358 $0.362 310 428
May 26, 2016 $0.370 $0.388 $0.360 $0.361 319 230
May 25, 2016 $0.365 $0.388 $0.365 $0.380 152 431
Click to get the best stock tips daily for free!

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745,... MDGL Profile

Golden Star

Ticker Date Change Price
CVBF May 01 2.75% $16.75
FTSL May 01 0.282% $46.03
EQC Apr 30 0.694% $18.72
HRB Apr 30 0.635% $47.23
BSCQ Apr 30 0.576% $19.09
BSJP Apr 29 0.306% $22.91
LYG Apr 29 1.56% $2.56
ORA Apr 29 4.68% $64.48
DHT Apr 24 3.10% $11.28
LPLA Apr 19 3.12% $262.59
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT